The JAK2 Gene Thrombocythemia Type 3 Somatic Genetic Test is a specialized diagnostic procedure designed to identify mutations in the JAK2 gene, which are closely associated with the development of Thrombocythemia Type 3, a rare myeloproliferative disorder characterized by the overproduction of platelets in the blood. This condition can lead to various complications, including an increased risk of blood clots, bleeding, and other serious cardiovascular events. The test is conducted on a sample of the patient's blood or bone marrow to detect the presence of specific somatic mutations in the JAK2 gene, which are not inherited but occur during a person's lifetime.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test offers a critical tool for the accurate diagnosis and management of Thrombocythemia Type 3. By identifying the genetic underpinnings of the disorder, healthcare providers can tailor treatment strategies more effectively, potentially improving patient outcomes. The cost of the test is 4400 AED, reflecting the specialized nature of the genetic analysis and the sophisticated technology employed in detecting these mutations. For patients and healthcare professionals in the UAE, DNA Labs UAE represents a reliable option for advanced genetic testing, providing vital information for the management of complex hematological disorders.
The SRGAP1 Gene Thyroid Cancer Type 2 Nonmedullary Susceptibility Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to assess the risk of developing Type 2 Nonmedullary Thyroid Cancer (NMTC2) through the analysis of the SRGAP1 gene. This gene has been implicated in influencing an individual's susceptibility to NMTC2, a variant of thyroid cancer that is distinct from the more commonly known medullary type. The test seeks to identify specific genetic mutations or alterations within the SRGAP1 gene that might increase the likelihood of an individual developing this form of thyroid cancer.
Priced at 4400 AED, the test offers a valuable resource for those with a family history of thyroid cancer or who have been identified as being at a higher risk due to genetic predispositions. Conducted at the state-of-the-art facilities of DNA Labs UAE, the test involves a simple sample collection process, followed by detailed genetic analysis. The results provide crucial insights into the patient's genetic risk factors, enabling proactive health management strategies, including regular monitoring and preventive measures to mitigate the risk of developing NMTC2.
By opting for the SRGAP1 Gene Thyroid Cancer Type 2 Nonmedullary Susceptibility Genetic Test, individuals gain access to personalized health information that can guide decision-making processes regarding their health and well-being, potentially leading to early detection and more effective management of thyroid cancer risks.
The CYLD Gene Trichoepithelioma Multiple Familial Type 1 Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the CYLD gene, which are linked to the development of Trichoepithelioma Multiple Familial Type 1. This condition is a rare genetic disorder characterized by the appearance of multiple benign skin tumors, primarily affecting the face, scalp, and neck. These tumors, known as trichoepitheliomas, typically begin to develop in late childhood or adolescence.
This genetic test is crucial for families with a history of this condition, as it allows for the early identification of affected individuals. Early diagnosis can lead to timely intervention and management of the condition, potentially reducing the physical and psychological impact of the skin tumors. The test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory for mutations in the CYLD gene.
The cost of the CYLD Gene Trichoepithelioma Multiple Familial Type 1 Genetic Test at DNA Labs UAE is 4400 AED. This cost reflects the specialized nature of the test and the comprehensive analysis required to accurately identify the genetic mutation. For individuals with a family history of Trichoepithelioma Multiple Familial Type 1, this test provides a valuable resource for genetic counseling and planning for future healthcare needs.
BAP1 Gene Tumor Predisposition Syndrome Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the BAP1 gene, which are associated with an increased risk of developing various types of cancer. This gene plays a crucial role in DNA repair, cell cycle regulation, and apoptosis. Mutations in BAP1 can lead to a hereditary condition known as BAP1 tumor predisposition syndrome (BAP1-TPDS), which predisposes individuals to a range of cancers, including uveal melanoma, mesothelioma, cutaneous melanoma, and renal cell carcinoma, among others.
The test, available at DNA Labs UAE, involves analyzing the individual's DNA, extracted from a blood sample, to detect any alterations in the BAP1 gene. It is particularly recommended for individuals with a family history of related cancers or those who have been diagnosed with conditions that could be linked to BAP1-TPDS.
The cost of the BAP1 Gene Tumor Predisposition Syndrome Genetic Test at DNA Labs UAE is 4400 AED. This price may cover the genetic counseling that is often recommended before and after genetic testing. This counseling helps individuals understand the implications of the test results, including the potential need for increased surveillance, preventive measures, or further genetic testing for family members.
ARL11 Gene Tumor Predisposition Syndrome is a rare genetic condition linked to an increased risk of developing various types of tumors. The condition is associated with mutations in the ARL11 gene, which plays a crucial role in the regulation of cell growth and apoptosis. Individuals carrying mutations in this gene may be predisposed to a higher risk of cancer, making early detection and monitoring essential for managing their health.
The ARL11 Related Genetic Test is a specialized diagnostic tool designed to identify mutations in the ARL11 gene. This test is crucial for individuals with a family history of cancer or those who are at an increased risk of developing tumors associated with the ARL11 gene mutation. By detecting these mutations, the test can provide valuable information that helps in the early diagnosis, targeted treatment, and management of the condition, potentially improving the patient's prognosis.
This genetic test is available at DNA Labs UAE, a leading facility known for its advanced genetic testing services. The cost of the ARL11 Related Genetic Test is 4400 AED. DNA Labs UAE employs state-of-the-art technology and follows stringent protocols to ensure the accuracy and reliability of the test results. Opting for this test at DNA Labs UAE not only offers individuals a chance to take proactive steps towards managing their health but also provides them with the support of highly skilled professionals throughout the testing process.
The RHBDF2 gene test for Tylosis with Esophageal Cancer is a specialized genetic assessment available at DNA Labs UAE. This test is designed to identify mutations in the RHBDF2 gene, which are associated with an increased risk of developing tylosis—a rare skin disorder characterized by thickening of the skin on the palms and soles—and esophageal cancer. Tylosis with esophageal cancer (TOC) is a hereditary condition, meaning that individuals with a family history of this condition are at a higher risk of developing it themselves.
The test is crucial for early detection and management of the condition, allowing for timely interventions and monitoring for those at risk. Conducted through a sample of blood or saliva, the procedure is straightforward and designed with patient convenience in mind.
The cost of the RHBDF2 gene test at DNA Labs UAE is 4400 AED. Given the potential life-saving implications of early detection and the specialized nature of the test, this cost is an investment in personal health and well-being for individuals with a family history of tylosis with esophageal cancer.
The VHL gene von Hippel-Lindau syndrome genetic test is a diagnostic tool used to identify mutations in the VHL gene, which are associated with von Hippel-Lindau syndrome. This inherited disorder predisposes individuals to a variety of benign and malignant tumors, including those affecting the brain, spinal cord, kidneys, pancreas, and adrenal glands. Early detection through genetic testing is crucial for managing the condition effectively and reducing the risk of complications.
Conducted at DNA Labs UAE, the test involves analyzing a sample of the patient's blood or saliva to search for abnormalities in the VHL gene that indicate the presence of von Hippel-Lindau syndrome. The cost of the test is 4400 AED, an investment that can provide invaluable information for affected individuals and their families. By confirming a diagnosis, the test enables tailored surveillance and treatment strategies, aiming to improve the quality of life and outcomes for those with the condition.
The "All Panel Cytogenetics and FISH BCR-ABL TEL-AML1 MLL E2A Test" is a comprehensive diagnostic examination conducted at DNA Labs UAE, designed to detect chromosomal abnormalities and specific genetic mutations that are often associated with various types of leukemia and other hematologic disorders. This test employs both Cytogenetics and Fluorescence In Situ Hybridization (FISH) techniques to identify the presence of genetic alterations such as the BCR-ABL fusion gene, TEL-AML1 (ETV6-RUNX1) translocation, MLL (KMT2A) rearrangements, and E2A (TCF3) translocations. These genetic markers are critical for diagnosing conditions like Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and other related blood cancers. The identification of these specific genetic abnormalities aids in determining prognosis, guiding treatment decisions, and monitoring response to therapy. The test is priced at 4400 AED, reflecting the comprehensive and sophisticated nature of the analysis conducted by DNA Labs UAE, a facility known for its advanced diagnostic capabilities and expertise in genetic testing.
The "AML Prognostic Panel" is a comprehensive diagnostic test designed for patients diagnosed with Acute Myeloid Leukemia (AML), a type of cancer that affects the blood and bone marrow. This panel includes a variety of genetic tests that help in determining the prognosis of AML patients, guiding treatment decisions, and predicting treatment response. The key components of this panel are Cytogenetics and Polymerase Chain Reaction (PCR) tests targeting specific genetic markers, including AMLETO INV16, PML-RARA, FLT3, NPM1, and CEBPA.
1. **Cytogenetics** - This test looks at the chromosomes of cells from samples of peripheral blood or bone marrow to identify any genetic abnormalities that might be driving the leukemia.
2. **PCR (Polymerase Chain Reaction)** - PCR is a highly sensitive technique used to amplify and detect specific genetic mutations and rearrangements that are known to be associated with AML.
- **AMLETO INV16** (also known as CBFB-MYH11) - A specific chromosomal abnormality that can be detected in AML patients, which can influence treatment choices.
- **PML-RARA** - Associated with Acute Promyelocytic Leukemia (APL), a subtype of AML, this genetic marker is crucial for diagnosis and monitoring response to therapy.
- **FLT3** - Mutations in the FLT3 gene are common in AML and are associated with a poor prognosis. Testing for FLT3 mutations helps in risk stratification and may guide therapy choices.
- **NPM1** - Mutations in the NPM1 gene are among the most common genetic changes in AML and can have implications for prognosis and treatment.
- **CEBPA** - Mutations in the CEBPA gene are associated with a favorable prognosis in some cases of AML.
Performed at DNA Labs UAE, a leading diagnostic laboratory, the AML Prognostic Panel offers a thorough genetic analysis for AML patients. The cost of the test is 4400 AED, reflecting the comprehensive nature of the panel and the advanced technologies employed. By providing detailed genetic insights, this test plays a critical role in tailoring treatment strategies to individual patients, ultimately aiming to improve outcomes in AML management.
The "Multiplex Panel Cytogenetics and PCR for 28 Translocations and 80 Breakpoints CML AML ALL Test" is a sophisticated diagnostic tool offered by DNA Labs UAE, designed to detect chromosomal abnormalities associated with various forms of leukemia, including Chronic Myeloid Leukemia (CML), Acute Myeloid Leukemia (AML), and Acute Lymphoblastic Leukemia (ALL). Utilizing cutting-edge multiplex panel cytogenetics alongside Polymerase Chain Reaction (PCR) technology, this test can identify up to 28 different translocations and 80 breakpoints, providing a comprehensive genetic profile that is crucial for the accurate diagnosis, prognosis, and treatment planning for patients suffering from these hematologic malignancies.
The test is priced at 4200 AED, reflecting the complexity and the detailed insights it offers into the genetic alterations associated with leukemia. By pinpointing specific translocations and breakpoints, healthcare providers can tailor treatment strategies to the individual patient, potentially improving outcomes and minimizing the risk of unnecessary side effects. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a significant advancement in the personalized medicine approach to leukemia treatment, offering hope and optimized care to patients battling these challenging conditions.
